Is prazosin dialyzable?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Is Prazosin Dialyzable?

No, prazosin is not dialyzable because it is highly protein bound (92-97%), which prevents effective removal by hemodialysis. 1

Primary Evidence from FDA Labeling

The FDA drug label explicitly states that "prazosin hydrochloride is not dialyzable because it is protein bound." 1 This is the definitive answer based on the highest-priority evidence source.

Pharmacokinetic Basis for Non-Dialyzability

The pharmacokinetic properties of prazosin explain why dialysis is ineffective:

  • Extensive protein binding: Prazosin is 92-97% bound to plasma proteins (albumin and alpha-1-acid glycoprotein), which is independent of plasma concentration in the therapeutic range. 2

  • Large volume of distribution: The steady-state volume of distribution is 42.2 ± 8.9L, indicating extensive tissue distribution beyond the plasma compartment. 2

  • Hepatic metabolism predominates: Prazosin undergoes extensive first-pass metabolism by the liver, with only 6% excreted unchanged (mainly in urine), while the two main metabolites are almost completely excreted in bile. 2

Clinical Implications

In Overdose Management

If prazosin overdose leads to hypotension, dialysis should not be considered as a treatment modality. 1 Instead, management should focus on:

  • Keeping the patient supine to restore blood pressure 1
  • Volume expanders as first-line shock treatment 1
  • Vasopressors if volume expansion is inadequate 1
  • Monitoring and supporting renal function 1

In Renal Failure Patients

Prazosin can be safely used in patients with impaired renal function without dose adjustment based on dialysis status:

  • Elimination kinetics are virtually identical regardless of degree of renal function 3
  • No drug accumulation occurs with repeated dosing in renal impairment 3
  • The elimination half-life may be prolonged in chronic renal failure, but this is due to altered protein binding and pharmacodynamics, not dialyzability 2
  • Prazosin is effective for hypertension control in hemodialysis patients at doses of 5-40 mg daily, either alone or with additional antihypertensives 4

Dosing Considerations

While prazosin is not removed by dialysis, dosage should still be titrated cautiously in patients with chronic renal failure due to increased plasma free fraction and prolonged elimination half-life from altered protein binding. 2

References

Research

Clinical pharmacokinetics of prazosin.

Clinical pharmacokinetics, 1980

Research

Prazosin kinetics and effectiveness in renal failure.

Clinical pharmacology and therapeutics, 1980

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.